Last 12 months
Inside the activity.
14 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 14 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2022 Filed May 25, 2022 22:34 UTC |
PARMAR KUSHDirector · 10% owner
|
SaleCommon Stock | 66,447 | $13.00 | $863,811.00 |
DisclosureSEC source: 0001209191-22-031969 · doc4.xml · nonDerivative · entry 1 PARMAR KUSH · CIK 0001664281 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By 5AM Ventures V, L.P. Disclosed balance after: 2,578,640 F1 · ownership.nature: These securities are held directly by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC ("Partners V") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:31 UTC |
5AM Opportunities I, L.P.10% owner
Schwab Andrew J.10% owner
5AM Opportunities I (GP), LLC10% owner
5AM Partners V, LLC10% owner
5AM Ventures V, L.P.10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 66,447 | $13.00 | $863,811.00 |
DisclosureSEC source: 0001209191-22-031966 · doc4.xml · nonDerivative · entry 2 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By 5AM Ventures V, L.P. Disclosed balance after: 2,578,640 F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC is the general partner of Ventures V and may be deemed to have sole investment and voting power over the shares held by Ventures V. Each of Andrew Schwab, Dr. Kush Parmar and Dr. Scott Rocklage is a Managing Member of 5AM Partners V, LLC, and may be deemed to have shared voting and dispositive power over the shares held by Ventures V. Therefore, each of Andrew Schwab, Dr. Kush Parmar, Dr. Scott Rocklage, and 5AM Partners V, LLC may be deemed to beneficially own the shares held by Ventures V, and each disclaims beneficial ownership over the shares held by Ventures V except to the extent of his or its pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:31 UTC |
5AM Opportunities I, L.P.10% owner
Schwab Andrew J.10% owner
5AM Opportunities I (GP), LLC10% owner
5AM Partners V, LLC10% owner
5AM Ventures V, L.P.10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 33,553 | $13.00 | $436,189.00 |
DisclosureSEC source: 0001209191-22-031966 · doc4.xml · nonDerivative · entry 1 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By 5AM Opportunities I, L.P. Disclosed balance after: 1,302,084 F1 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities I"). 5AM Opportunities I (GP), LLC is the general partner of Opportunities I and may be deemed to have sole investment and voting power over the shares held by Opportunities I. Each of Andrew Schwab and Dr. Kush Parmar is a Managing Member of 5AM Opportunities I (GP), LLC, and may be deemed to have shared voting and dispositive power over the shares held by Opportunities I. Therefore, each of Andrew Schwab, Dr. Kush Parmar and 5AM Opportunities I(GP), LLC may be deemed to beneficially own the shares held by Opportunities I, and each disclaims beneficial ownership over the shares held by Opportunities I except to the extent of his or its pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports. Read SEC document |
| April 04, 2022 Filed Apr 7, 2022 00:28 UTC |
Nash Christine ADirector
|
GrantOption (Right to Buy) · Derivative | 26,880 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-22-014169 · doc4.xml · derivative · entry 1 Nash Christine A · CIK 0001554403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,880 Underlying: Common Stock · 26,880 shares Expires 2032-04-04 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in three equal annual installments beginning on April 4, 2023. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 23:59 UTC |
Liu HuiDirector
|
GrantOption (Right to Buy) · Derivative | 26,880 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-22-014167 · doc4.xml · derivative · entry 1 Liu Hui · CIK 0001790518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,880 Underlying: Common Stock · 26,880 shares Expires 2032-04-04 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in three equal annual installments beginning on April 4, 2023. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 21:30 UTC |
Fryer Jeffrey MSee Remarks
|
PurchaseCommon Stock | 3,000 | $8.04 | $24,120.00 |
DisclosureSEC source: 0000899243-22-011950 · doc4.xml · nonDerivative · entry 1 Fryer Jeffrey M · CIK 0001872879 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,048 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.00 to $8.99, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. F2 · ownership.nature: Shares of common stock are held in a Roth IRA. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 23:24 UTC |
5AM Opportunities I, L.P.10% owner
Schwab Andrew J.10% owner
5AM Opportunities I (GP), LLC10% owner
5AM Partners V, LLC10% owner
5AM Ventures V, L.P.10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 139,539 | $13.05 | $1,820,983.95 |
DisclosureSEC source: 0001209191-22-008584 · doc4.xml · nonDerivative · entry 2 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,645,087 F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC is the general partner of Ventures V and may be deemed to have sole investment and voting power over the shares held by Ventures V. Each of Andrew Schwab, Dr. Kush Parmar and Dr. Scott Rocklage is a Managing Member of 5AM Partners V, LLC, and may be deemed to have shared voting and dispositive power over the shares held by Ventures V. Therefore, each of Andrew Schwab, Dr. Kush Parmar, Dr. Scott Rocklage, and 5AM Partners V, LLC may be deemed to beneficially own the shares held by Ventures V, and each disclaims beneficial ownership over the shares held by Ventures V except to the extent of his or its pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 23:24 UTC |
5AM Opportunities I, L.P.10% owner
Schwab Andrew J.10% owner
5AM Opportunities I (GP), LLC10% owner
5AM Partners V, LLC10% owner
5AM Ventures V, L.P.10% owner
ROCKLAGE SCOTT M10% owner
|
SaleCommon Stock | 70,461 | $13.05 | $919,516.05 |
DisclosureSEC source: 0001209191-22-008584 · doc4.xml · nonDerivative · entry 1 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,335,637 F1 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities I"). 5AM Opportunities I (GP), LLC is the general partner of Opportunities I and may be deemed to have sole investment and voting power over the shares held by Opportunities I. Each of Andrew Schwab and Dr. Kush Parmar is a Managing Member of 5AM Opportunities I (GP), LLC, and may be deemed to have shared voting and dispositive power over the shares held by Opportunities I. Therefore, each of Andrew Schwab, Dr. Kush Parmar and 5AM Opportunities I(GP), LLC may be deemed to beneficially own the shares held by Opportunities I, and each disclaims beneficial ownership over the shares held by Opportunities I except to the extent of his or its pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 23:22 UTC |
PARMAR KUSHDirector
|
SaleCommon Stock | 70,461 | $13.05 | $919,516.05 |
DisclosureSEC source: 0001209191-22-008579 · doc4.xml · nonDerivative · entry 2 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Opportunities I, L.P. Disclosed balance after: 1,335,637 F2 · ownership.nature: These securities are held directly by 5AM Opportunities I, L.P. ("Opportunities I, L.P."). 5AM Opportunities I (GP), LLC ("Opportunities I (GP)") is the general partner of Opportunities I, L.P. Dr. Parmar is a managing member of Opportunities I (GP), and may be deemed to share voting and dispositive power over the securities held by Opportunities I, L.P. Dr. Parmar disclaims beneficial ownership of the securities held by Opportunities I, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 23:22 UTC |
PARMAR KUSHDirector
|
SaleCommon Stock | 139,539 | $13.05 | $1,820,983.95 |
DisclosureSEC source: 0001209191-22-008579 · doc4.xml · nonDerivative · entry 1 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Ventures V, L.P. Disclosed balance after: 2,645,087 F1 · ownership.nature: These securities are held directly by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC ("Partners V") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:44 UTC |
Fryer Jeffrey MChief Financial Officer
|
GrantOption (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-22-005526 · doc4.xml · derivative · entry 1 Fryer Jeffrey M · CIK 0001872879 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 7, 2026. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:39 UTC |
Uden StephenSee Remarks
|
GrantOption (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-22-005521 · doc4.xml · derivative · entry 1 Uden Stephen · CIK 0001332141 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 7, 2026. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:38 UTC |
MACKAY MARTINDirector · Chief Executive Officer
|
GrantOption (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-22-005519 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 7, 2026. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:37 UTC |
Ryder StevenChief Medical Officer
|
GrantOption (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-22-005518 · doc4.xml · derivative · entry 1 Ryder Steven · CIK 0001872868 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 7, 2026. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 23:22 UTC |
Fryer Jeffrey MSee Remarks
|
PurchaseCommon Stock | 1,400 | $8.70 | $12,180.00 |
DisclosureSEC source: 0000899243-22-002911 · doc4.xml · nonDerivative · entry 1 Fryer Jeffrey M · CIK 0001872879 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 44,048 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: Shares of common stock are held in a Roth IRA. Read SEC document |
| January 13, 2022 Filed Jan 15, 2022 01:11 UTC |
Uden StephenSee Remarks
|
PurchaseCommon Stock | 807 | $9.62 | $7,763.34 |
DisclosureSEC source: 0000899243-22-002043 · doc4.xml · nonDerivative · entry 4 Uden Stephen · CIK 0001332141 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,127 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.29 to $10.28, inclusive. Read SEC document |
| January 13, 2022 Filed Jan 15, 2022 01:11 UTC |
Uden StephenSee Remarks
|
PurchaseCommon Stock | 4,193 | $9.06 | $37,988.58 |
DisclosureSEC source: 0000899243-22-002043 · doc4.xml · nonDerivative · entry 3 Uden Stephen · CIK 0001332141 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,320 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.29 to $9.28, inclusive. Read SEC document |
| January 12, 2022 Filed Jan 15, 2022 01:11 UTC |
Uden StephenSee Remarks
|
PurchaseCommon Stock | 5,000 | $10.55 | $52,750.00 |
DisclosureSEC source: 0000899243-22-002043 · doc4.xml · nonDerivative · entry 2 Uden Stephen · CIK 0001332141 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,127 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 23:56 UTC |
MACKAY MARTINDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,496 | $10.65 | $47,882.40 |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · nonDerivative · entry 4 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,609 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:56 UTC |
MACKAY MARTINDirector · Chief Executive Officer
|
PurchaseCommon Stock | 5,504 | $10.10 | $55,590.40 |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · nonDerivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,113 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.66 to $10.65, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 01:03 UTC |
Fryer Jeffrey MSee Remarks
|
PurchaseCommon Stock | 9,295 | $9.44 | $87,744.80 |
DisclosureSEC source: 0000899243-22-001629 · doc4.xml · nonDerivative · entry 6 Fryer Jeffrey M · CIK 0001872879 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 42,648 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $10.00, inclusive. F2 · ownership.nature: Shares of common stock are held in a Roth IRA. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 01:03 UTC |
Fryer Jeffrey MSee Remarks
|
PurchaseCommon Stock | 705 | $8.97 | $6,323.85 |
DisclosureSEC source: 0000899243-22-001629 · doc4.xml · nonDerivative · entry 5 Fryer Jeffrey M · CIK 0001872879 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 33,353 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.01 to $9.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4. F2 · ownership.nature: Shares of common stock are held in a Roth IRA. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:44 UTC |
Hopfner Robert LorneDirector
|
GrantOption (Right to Buy) · Derivative | 6,242 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0000899243-22-001062 · doc4.xml · derivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,242 Underlying: Common Stock · 6,242 shares Expires 2032-01-03 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:41 UTC |
HUNT RONALDDirector
|
GrantOption (Right to Buy) · Derivative | 6,242 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0000899243-22-001060 · doc4.xml · derivative · entry 1 HUNT RONALD · CIK 0001247851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,242 Underlying: Common Stock · 6,242 shares Expires 2032-01-03 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:38 UTC |
PARMAR KUSHDirector
|
GrantOption (Right to Buy) · Derivative | 5,772 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0000899243-22-001058 · doc4.xml · derivative · entry 1 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,772 Underlying: Common Stock · 5,772 shares Expires 2032-01-03 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:38 UTC |
SHANNON TIMOTHY MDirector
|
GrantOption (Right to Buy) · Derivative | 6,041 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0000899243-22-001057 · doc4.xml · derivative · entry 1 SHANNON TIMOTHY M · CIK 0001207114 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041 Underlying: Common Stock · 6,041 shares Expires 2032-01-03 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:37 UTC |
Soteropoulos PaulaDirector
|
GrantOption (Right to Buy) · Derivative | 5,369 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0000899243-22-001056 · doc4.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires 2032-01-03 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 19:23 UTC |
FMR LLCSee Remark 1
|
ConversionSeries B Preferred Units · Derivative | 10,789,193 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-21-001650 · primary_doc.xml · derivative · entry 2 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 0 Underlying: Common Stock · 1,694,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On August 2, 2021 , in connection with the completion of the issuer's initial public offering, holders of Series B Preferred Units of Rallybio Holdings, LLC received an aggregate of 16,402,235 shares of common stock of Rallybio Corporation. As a result, F-Prime Capital Partners Life Sciences Fund VI LP received 1,694,388 common shares upon closing without payment of further consideration. F1 · price: On August 2, 2021 , in connection with the completion of the issuer's initial public offering, holders of Series B Preferred Units of Rallybio Holdings, LLC received an aggregate of 16,402,235 shares of common stock of Rallybio Corporation. As a result, F-Prime Capital Partners Life Sciences Fund VI LP received 1,694,388 common shares upon closing without payment of further consideration. F1 · derivative.exercise_date: On August 2, 2021 , in connection with the completion of the issuer's initial public offering, holders of Series B Preferred Units of Rallybio Holdings, LLC received an aggregate of 16,402,235 shares of common stock of Rallybio Corporation. As a result, F-Prime Capital Partners Life Sciences Fund VI LP received 1,694,388 common shares upon closing without payment of further consideration. F1 · derivative.expiration_date: On August 2, 2021 , in connection with the completion of the issuer's initial public offering, holders of Series B Preferred Units of Rallybio Holdings, LLC received an aggregate of 16,402,235 shares of common stock of Rallybio Corporation. As a result, F-Prime Capital Partners Life Sciences Fund VI LP received 1,694,388 common shares upon closing without payment of further consideration. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 19:23 UTC |
FMR LLCSee Remark 1
|
ConversionCommon Stock | 1,694,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000315066-21-001650 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 1,694,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 2, 2021 , in connection with the completion of the issuer's initial public offering, holders of Series B Preferred Units of Rallybio Holdings, LLC received an aggregate of 16,402,235 shares of common stock of Rallybio Corporation. As a result, F-Prime Capital Partners Life Sciences Fund VI LP received 1,694,388 common shares upon closing without payment of further consideration. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
PurchaseCommon Stock | 615,384 | $13.00 | $7,999,992.00 |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · nonDerivative · entry 3 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Opportunities I, L.P. Disclosed balance after: 1,406,098 F3 · ownership.nature: These securities are held directly by 5AM Opportunities I, L.P. ("Opportunities I, L.P."). 5AM Opportunities I (GP), LLC ("Opportunities I (GP)") is the general partner of Opportunities I, L.P. Dr. Parmar is a managing member of Opportunities I (GP), and may be deemed to share voting and dispositive power over the securities held by Opportunities I, L.P. Dr. Parmar disclaims beneficial ownership of the securities held by Opportunities I, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 01:17 UTC |
5AM Opportunities I, L.P.10% owner
Schwab Andrew J.10% owner
5AM Opportunities I (GP), LLC10% owner
5AM Partners V, LLC10% owner
5AM Ventures V, L.P.10% owner
ROCKLAGE SCOTT M10% owner
|
PurchaseCommon Stock | 615,384 | $13.00 | $7,999,992.00 |
DisclosureSEC source: 0001209191-21-049821 · doc4.xml · nonDerivative · entry 1 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,406,098 F1 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities I"). 5AM Opportunities I (GP), LLC is the general partner of Opportunities I and may be deemed to have sole investment and voting power over the shares held by Opportunities I. Each of Andrew Schwab and Dr. Kush Parmar is a Managing Member of 5AM Opportunities I (GP), LLC, and may be deemed to have shared voting and dispositive power over the shares held by Opportunities I. Therefore, each of Andrew Schwab, Dr. Kush Parmar and 5AM Opportunities I(GP), LLC may be deemed to beneficially own the shares held by Opportunities I, and each disclaims beneficial ownership over the shares held by Opportunities I except to the extent of his or its pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:52 UTC |
Hopfner Robert LorneDirector
|
PurchaseCommon Stock | 576,923 | $13.00 | $7,499,999.00 |
DisclosureSEC source: 0000899243-21-031635 · doc4.xml · nonDerivative · entry 2 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pivotal bioVenture Partners Fund I L.P Disclosed balance after: 2,267,411 F2 · ownership.nature: Shares of common stock are held directly by Pivotal bioVenture Partners Fund I L.P. ("Pivotal"). Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal. Dr. Hopfner is a managing director at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal. Dr. Hopfner disclaims beneficial ownership of the shares held by Pivotal except to the extent of his pecuniary interest therein. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:51 UTC |
HUNT RONALDDirector
|
PurchaseCommon Stock | 153,846 | $13.00 | $1,999,998.00 |
DisclosureSEC source: 0000899243-21-031634 · doc4.xml · nonDerivative · entry 3 HUNT RONALD · CIK 0001247851 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,301,603 F3 · ownership.nature: Shares are directly held by New Leaf Biopharma Opportunities II, L.P. ("NL BPO-II"). New Leaf BPO Associates II, L.P. ("NL BPOA-II LP") is the general partner of NL BPO-II and New Leaf BPO Management II, L.L.C. ("NL BPOA-II LLC) is the general partner of NL BPOA-II LP. The Reporting Person is a managing director of NL BPOA-II LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NL BPO-II. The Reporting Person disclaims beneficial ownership of the shares held by NL BPO-II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:51 UTC |
HUNT RONALDDirector
|
PurchaseCommon Stock | 153,846 | $13.00 | $1,999,998.00 |
DisclosureSEC source: 0000899243-21-031634 · doc4.xml · nonDerivative · entry 2 HUNT RONALD · CIK 0001247851 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,147,757 F2 · ownership.nature: Shares are directly held by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:50 UTC |
SHANNON TIMOTHY MDirector
|
PurchaseCommon Stock | 76,923 | $13.00 | $999,999.00 |
DisclosureSEC source: 0000899243-21-031633 · doc4.xml · nonDerivative · entry 2 SHANNON TIMOTHY M · CIK 0001207114 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Canaan XI L.P. Disclosed balance after: 2,409,712 F2 · ownership.nature: The reported securities are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. The Reporting Person is a manager and member of Canaan XI. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interest he owns in Canaan XI. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:40 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionSeries B Preferred Units · Derivative | 21,578,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-007995 · ownership.xml · derivative · entry 3 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Common Stock · 3,388,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B Preferred Units were convertible into Common Stock on a 1:0.157 basis into the number of shares of Common Stock at the Reporting Person's election and were automatically converted upon the closing of the initial public offering of Rallybio Corporation (the "Issuer"). The shares had no expiration date. F5 · price: The Series B Preferred Units were convertible into Common Stock on a 1:0.157 basis into the number of shares of Common Stock at the Reporting Person's election and were automatically converted upon the closing of the initial public offering of Rallybio Corporation (the "Issuer"). The shares had no expiration date. F5 · derivative.exercise_date: The Series B Preferred Units were convertible into Common Stock on a 1:0.157 basis into the number of shares of Common Stock at the Reporting Person's election and were automatically converted upon the closing of the initial public offering of Rallybio Corporation (the "Issuer"). The shares had no expiration date. F5 · derivative.expiration_date: The Series B Preferred Units were convertible into Common Stock on a 1:0.157 basis into the number of shares of Common Stock at the Reporting Person's election and were automatically converted upon the closing of the initial public offering of Rallybio Corporation (the "Issuer"). The shares had no expiration date. F1 · ownership.nature: Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund"). Each of VGI, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F2 · ownership.nature: On July 27, 2021, Opportunities Fund acquired 806,000 shares of common stock of the Issuer ("Common Stock") at a price of $13.00 per share in connection with the Issuer's (as defined below) initial public offering. VGI provides managerial services to Opportunities Fund, which directly holds the 4,194,777 shares of Common Stock reported herein. Because of the relationship between VGI and VGOP, VGI may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. F3 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. F4 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:40 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
PurchaseCommon Stock | 806,000 | $13.00 | $10,478,000.00 |
DisclosureSEC source: 0001387131-21-007995 · ownership.xml · nonDerivative · entry 2 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation Responses Disclosed balance after: 4,194,777 F1 · ownership.nature: Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund"). Each of VGI, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F2 · ownership.nature: On July 27, 2021, Opportunities Fund acquired 806,000 shares of common stock of the Issuer ("Common Stock") at a price of $13.00 per share in connection with the Issuer's (as defined below) initial public offering. VGI provides managerial services to Opportunities Fund, which directly holds the 4,194,777 shares of Common Stock reported herein. Because of the relationship between VGI and VGOP, VGI may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. F3 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. F4 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:40 UTC |
VIKING GLOBAL INVESTORS LP10% owner
Viking Global Opportunities GP LLC10% owner
HALVORSEN OLE ANDREAS10% owner
Ott David C.10% owner
Shabet Rose Sharon10% owner
|
ConversionCommon Stock | 3,388,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-007995 · ownership.xml · nonDerivative · entry 1 VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner Ott David C. · CIK 0001621842 · 10% owner Shabet Rose Sharon · CIK 0001711393 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation Responses Disclosed balance after: 3,388,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series B Preferred Units were convertible into Common Stock on a 1:0.157 basis into the number of shares of Common Stock at the Reporting Person's election and were automatically converted upon the closing of the initial public offering of Rallybio Corporation (the "Issuer"). The shares had no expiration date. F1 · ownership.nature: Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund"). Each of VGI, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively the "Reporting Persons") may be deemed to beneficially own the shares reported on this form. F2 · ownership.nature: On July 27, 2021, Opportunities Fund acquired 806,000 shares of common stock of the Issuer ("Common Stock") at a price of $13.00 per share in connection with the Issuer's (as defined below) initial public offering. VGI provides managerial services to Opportunities Fund, which directly holds the 4,194,777 shares of Common Stock reported herein. Because of the relationship between VGI and VGOP, VGI may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. F3 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. F4 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document |
| July 28, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
GrantOption (Right to Buy) · Derivative | 13,440 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · derivative · entry 8 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 13,440 shares Expires not disclosed F5 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. F5 · derivative.expiration_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. Read SEC document |
| July 28, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
OtherSeries B Preferred Units · Derivative | 5,034,955 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · derivative · entry 7 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Opportunities I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 790,714 shares Expires not disclosed F1 · derivative.exercise_price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F4 · derivative.underlying: Prior to the effectiveness of the Plan of Liquidation, the Preferred Units were convertible into common units of Rallybio Holdings, LLC. F3 · ownership.nature: These securities are held directly by 5AM Opportunities I, L.P. ("Opportunities I, L.P."). 5AM Opportunities I (GP), LLC ("Opportunities I (GP)") is the general partner of Opportunities I, L.P. Dr. Parmar is a managing member of Opportunities I (GP), and may be deemed to share voting and dispositive power over the securities held by Opportunities I, L.P. Dr. Parmar disclaims beneficial ownership of the securities held by Opportunities I, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
OtherSeries B Preferred Units · Derivative | 7,192,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · derivative · entry 6 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Ventures V, LP. Disclosed balance after: 0 Underlying: Common Stock · 1,129,592 shares Expires not disclosed F1 · derivative.exercise_price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F4 · derivative.underlying: Prior to the effectiveness of the Plan of Liquidation, the Preferred Units were convertible into common units of Rallybio Holdings, LLC. F2 · ownership.nature: These securities are held directly by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC ("Partners V") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
OtherSeries A-2 Preferred Units · Derivative | 8,742,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · derivative · entry 5 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Ventures V, LP. Disclosed balance after: 0 Underlying: Common Stock · 1,372,990 shares Expires not disclosed F1 · derivative.exercise_price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F4 · derivative.underlying: Prior to the effectiveness of the Plan of Liquidation, the Preferred Units were convertible into common units of Rallybio Holdings, LLC. F2 · ownership.nature: These securities are held directly by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC ("Partners V") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
OtherSeries A-1 Preferred Units · Derivative | 1,795,946 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · derivative · entry 4 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Ventures V, LP. Disclosed balance after: 0 Underlying: Common Stock · 282,044 shares Expires not disclosed F1 · derivative.exercise_price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F4 · derivative.underlying: Prior to the effectiveness of the Plan of Liquidation, the Preferred Units were convertible into common units of Rallybio Holdings, LLC. F2 · ownership.nature: These securities are held directly by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC ("Partners V") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
OtherCommon Stock | 790,714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · nonDerivative · entry 2 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Opportunities I, L.P. Disclosed balance after: 790,714 F1 · kind: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F3 · ownership.nature: These securities are held directly by 5AM Opportunities I, L.P. ("Opportunities I, L.P."). 5AM Opportunities I (GP), LLC ("Opportunities I (GP)") is the general partner of Opportunities I, L.P. Dr. Parmar is a managing member of Opportunities I (GP), and may be deemed to share voting and dispositive power over the securities held by Opportunities I, L.P. Dr. Parmar disclaims beneficial ownership of the securities held by Opportunities I, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 5, 2021 01:19 UTC |
PARMAR KUSHDirector
|
OtherCommon Stock | 2,784,626 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-049823 · doc4.xml · nonDerivative · entry 1 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 5AM Ventures V, L.P. Disclosed balance after: 2,784,626 F1 · kind: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F2 · ownership.nature: These securities are held directly by 5AM Ventures V, L.P. ("Ventures V"). 5AM Partners V, LLC ("Partners V") is the sole general partner of Ventures V. Dr. Parmar is a managing member of Partners V and may be deemed to share voting and investment power over the securities held by Ventures V. Dr. Parmar disclaims beneficial ownership of the securities held by Ventures V except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 4, 2021 21:52 UTC |
Hopfner Robert LorneDirector
|
GrantOption (Right to Buy) · Derivative | 13,440 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031635 · doc4.xml · derivative · entry 4 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 13,440 shares Expires not disclosed F4 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031. F4 · derivative.expiration_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031. Read SEC document |
| July 28, 2021 Filed Aug 4, 2021 21:52 UTC |
Hopfner Robert LorneDirector
|
OtherSeries B Preferred Units · Derivative | 10,789,193 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031635 · doc4.xml · derivative · entry 3 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pivotal bioVenture Partners Fund I L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,693,488 shares Expires not disclosed F1 · derivative.exercise_price: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F3 · derivative.underlying: Prior to the effectiveness of the Plan of Liquidation, the Preferred Units were convertible into shares of common units of Rallybio Holdings, LLC. F2 · ownership.nature: Shares of common stock are held directly by Pivotal bioVenture Partners Fund I L.P. ("Pivotal"). Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal. Dr. Hopfner is a managing director at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal. Dr. Hopfner disclaims beneficial ownership of the shares held by Pivotal except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 4, 2021 21:52 UTC |
Hopfner Robert LorneDirector
|
OtherCommon Stock | 1,694,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031635 · doc4.xml · nonDerivative · entry 1 Hopfner Robert Lorne · CIK 0001551966 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pivotal bioVenture Partners Fund I L.P Disclosed balance after: 1,694,388 F1 · kind: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F2 · ownership.nature: Shares of common stock are held directly by Pivotal bioVenture Partners Fund I L.P. ("Pivotal"). Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal. Dr. Hopfner is a managing director at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal. Dr. Hopfner disclaims beneficial ownership of the shares held by Pivotal except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2021 Filed Aug 4, 2021 21:51 UTC |
HUNT RONALDDirector
|
GrantOption (Right to Buy) · Derivative | 13,440 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031634 · doc4.xml · derivative · entry 7 HUNT RONALD · CIK 0001247851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 13,440 shares Expires not disclosed F5 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031. F5 · derivative.expiration_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031. Read SEC document |
| July 28, 2021 Filed Aug 4, 2021 21:51 UTC |
HUNT RONALDDirector
|
OtherSeries B Preferred Units · Derivative | 2,157,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031634 · doc4.xml · derivative · entry 6 HUNT RONALD · CIK 0001247851 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 338,878 shares Expires not disclosed F1 · derivative.exercise_price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · price: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation. F4 · derivative.underlying: Prior to the effectiveness of the Plan of Liquidation, the Preferred Units of Rallybio Holdings, LLC were convertible into shares of common units of Rallybio Holdings, LLC. F2 · ownership.nature: Shares are directly held by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.